{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T05:16:08Z","timestamp":1776748568072,"version":"3.51.2"},"reference-count":5,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2017,3,10]],"date-time":"2017-03-10T00:00:00Z","timestamp":1489104000000},"content-version":"vor","delay-in-days":9,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatric Dermatology"],"published-print":{"date-parts":[[2017,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Vismodegib is an oral inhibitor of the Hedgehog signaling pathway and has been used to treat basal cell carcinoma (<jats:styled-content style=\"fixed-case\">BCC<\/jats:styled-content>) in adults. This article reports clearance of a nodular <jats:styled-content style=\"fixed-case\">BCC<\/jats:styled-content> of the nasal tip in an 8\u2010year\u2010old boy with xeroderma pigmentosum (<jats:styled-content style=\"fixed-case\">XP<\/jats:styled-content>). <jats:styled-content style=\"fixed-case\">BCC<\/jats:styled-content> can pose therapeutic challenges when located in areas that are not amenable to traditional therapies such as Mohs micrographic surgery or topical agents. Vismodegib was used at a dose of 150\u00a0mg\/day to treat the boy's <jats:styled-content style=\"fixed-case\">BCC<\/jats:styled-content>. After 4\u00a0months of therapy, we achieved complete clinical clearance. During 21\u00a0months of follow\u2010up, the patient's nose remained clinically clear of tumor. Vismodegib was successfully used to treat a child with <jats:styled-content style=\"fixed-case\">XP<\/jats:styled-content> and nodular <jats:styled-content style=\"fixed-case\">BCC<\/jats:styled-content>. Our goal in using vismodegib was tumor regression while avoiding cosmetic and functional disfigurement. Vismodegib was effective in clinically clearing the tumor, and the patient has shown no signs of recurrence. Further studies are warranted.<\/jats:p>","DOI":"10.1111\/pde.13080","type":"journal-article","created":{"date-parts":[[2017,3,10]],"date-time":"2017-03-10T14:24:49Z","timestamp":1489155889000},"page":"163-165","source":"Crossref","is-referenced-by-count":19,"title":["Vismodegib Therapy for Basal Cell Carcinoma in an 8\u2010Year\u2010Old Chinese Boy with Xeroderma Pigmentosum"],"prefix":"10.1111","volume":"34","author":[{"given":"Douglas","family":"Fife","sequence":"first","affiliation":[{"name":"Surgical Dermatology Las Vegas Nevada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marko A.","family":"Laitinen","sequence":"additional","affiliation":[{"name":"School of Medicine University of Nevada Reno Nevada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David J.","family":"Myers","sequence":"additional","affiliation":[{"name":"Nellis Air Force Base Mike O'Callaghan Federal Medical Center Las Vegas Nevada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pamela B.","family":"Landsteiner","sequence":"additional","affiliation":[{"name":"Nellis Air Force Base Mike O'Callaghan Federal Medical Center Las Vegas Nevada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,3,10]]},"reference":[{"key":"e_1_2_5_2_1","first-page":"87","article-title":"Radiation therapy for patients with xeroderma pigmentosum","volume":"14","author":"Sakata K","year":"1996","journal-title":"Radiat Med"},{"key":"e_1_2_5_3_1","first-page":"605","article-title":"Hedgehog pathway in pediatric cancers: they're not just for brain tumors anymore","author":"Macdonald TJ","year":"2012","journal-title":"American Society of Clinical Oncology"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2008.01.027"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-1425"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2015.4330"}],"container-title":["Pediatric Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fpde.13080","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/pde.13080","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T21:30:28Z","timestamp":1696023028000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/pde.13080"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":5,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["10.1111\/pde.13080"],"URL":"https:\/\/doi.org\/10.1111\/pde.13080","archive":["Portico"],"relation":{},"ISSN":["0736-8046","1525-1470"],"issn-type":[{"value":"0736-8046","type":"print"},{"value":"1525-1470","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3]]}}}